Elif Nur Barut1, Seckin Engin1, Burak Barut2, Cansu Kaya3, Gokcen Kerimoglu3, Arzu Ozel2,4, Mine Kadioglu5. 1. Department of Pharmacology, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Turkey. 2. Deparment of Biochemistry, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Turkey. 3. Department of Histology and Embryology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey. 4. Drug and Pharmaceutical Technology Application and Research Center, Karadeniz Technical University, Trabzon, Turkey. 5. Faculty of Medicine, Department of Pharmacology, Karadeniz Technical University, 61080, Trabzon, Turkey. kadioglu20@gmail.com.
Abstract
PURPOSE: Hemorrhagic cystitis (HC) is defined as any types of acute or chronic inflammation of urinary bladder with several reasons. One of the most common causes of HC is cyclophosphamide (CYP), an effective antineoplastic agent, due to its urotoxic potential. Ambroxol (AMB) is a mucoactive drug that has been used for numerous respiratory diseases. Besides its mucolytic activity, AMB is a potent antioxidant and antiinflammatory agent that is becoming more attractive for the treatment of several oxidative/inflammatory disorders. The aim of this study was to evaluate the uroprotective potential of AMB in CYP-induced HC. METHOD: Male Balb/c mice were pretreated with AMB (30, 70, and 100 mg/kg) once a day for 3 consecutive days before HC induction with CYP (300 mg/kg). Mesna (30 mg/kg;i.p.), only drug in the management of CYP-induced HC, was administered 20 min before; 4 and 8 h after cystitis induction. The urinary bladders were harvested and evaluated in functional, biochemical, and histological studies. RESULTS: CYP-induced HC markedly reduced acetylcholine (ACh)-induced contractions in detrusor strips and AMB at 100 mg/kg caused a significant increase in the responsiveness to ACh. Pretreatment with AMB prevented the elevation of malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-α) level, reduction of total glutathione (GSH) that induced by CYP. However, treatment with AMB did not improve the bladder weight and some histological parameters. CONCLUSION: These results suggest that AMB pretreatment could improve CYP-induced HC via antioxidant and antiinflammatory activities.
PURPOSE:Hemorrhagic cystitis (HC) is defined as any types of acute or chronic inflammation of urinary bladder with several reasons. One of the most common causes of HC is cyclophosphamide (CYP), an effective antineoplastic agent, due to its urotoxic potential. Ambroxol (AMB) is a mucoactive drug that has been used for numerous respiratory diseases. Besides its mucolytic activity, AMB is a potent antioxidant and antiinflammatory agent that is becoming more attractive for the treatment of several oxidative/inflammatory disorders. The aim of this study was to evaluate the uroprotective potential of AMB in CYP-induced HC. METHOD: Male Balb/c mice were pretreated with AMB (30, 70, and 100 mg/kg) once a day for 3 consecutive days before HC induction with CYP (300 mg/kg). Mesna (30 mg/kg;i.p.), only drug in the management of CYP-induced HC, was administered 20 min before; 4 and 8 h after cystitis induction. The urinary bladders were harvested and evaluated in functional, biochemical, and histological studies. RESULTS:CYP-induced HC markedly reduced acetylcholine (ACh)-induced contractions in detrusor strips and AMB at 100 mg/kg caused a significant increase in the responsiveness to ACh. Pretreatment with AMB prevented the elevation of malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-α) level, reduction of total glutathione (GSH) that induced by CYP. However, treatment with AMB did not improve the bladder weight and some histological parameters. CONCLUSION: These results suggest that AMB pretreatment could improve CYP-induced HC via antioxidant and antiinflammatory activities.
Authors: Rehab Sabri Abdelrahman; Eman Mohamad El Nashar; Mansour Abdullah Alghamdi; Khulood Mohammed Al-Khater; Reham Ismail Taha Journal: Int Urol Nephrol Date: 2022-07-11 Impact factor: 2.266
Authors: Ayman M Mousa; Khaled S Allemailem; Fahad A Alhumaydhi; Faris Alrumaihi; Ahmad Almatroudi; Ameen S Alwashmi; Mohammad Aljasir; Osamah Al Rugaie; Abdullah S M Aljohani; Khaled E A Soliman; Mohamad Y Rezk; Ahmed M S Hegazy; Hanan S Seleem Journal: J Inflamm Res Date: 2021-11-08
Authors: Ayman M Mousa; Khaled S Allemailem; Fahad A Alhumaydhi; Faris Alrumaihi; Ahmad Almatroudi; Mohammad Aljasir; Ameen S S Alwashmi; Osamah Al Rugaie; Khaled E A Soliman; Abdullah S M Aljohani; Waleed Al Abdulmonem; Ahmed A Ahmed; Arif Khan; Masood A Khan; Naif AlSuhaymi; Mahdi H Alsugoor; Wafa Abdullah Al-Megrin; Abulmaaty M Elsayed Journal: Evid Based Complement Alternat Med Date: 2022-03-17 Impact factor: 2.629
Authors: Andrzej Wróbel; Anna Serefko; Aleksandra Szopa; Daniela Ulrich; Ewa Poleszak; Tomasz Rechberger Journal: Front Pharmacol Date: 2020-07-08 Impact factor: 5.810
Authors: Anna Merwid-Ląd; Piotr Ziółkowski; Marta Szandruk-Bender; Agnieszka Matuszewska; Adam Szeląg; Małgorzata Trocha Journal: Pharmaceuticals (Basel) Date: 2021-11-29